Drug Profile
Research programme: pain therapeutics - Ampika
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Ampika
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Pain in United Kingdom
- 11 Aug 2016 Research programme: pain therapeutics anti-infectives - Ampika is available for licensing as of 11 Aug 2016. http://www.ampika.com/
- 11 Aug 2016 Early research in Pain in United Kingdom (unspecified route)